Drug · CHEMBL982
NALMEFENE
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. NALMEFENE. Drugs and targets, record CHEMBL982. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL982
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Other names
- JF-1, JKB-121, Nalmefeno, Nalmetrene, ORF 1167, ORF 11676, ORF-1167, ORF-11676, SRD-174, SRD174
- ChEMBL
- Open Targets' highest stage
- Approval, for 3 of its 14 diseases, from ATC, EMA Human Drugs and TTD
- Open Targets
Targets3
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| OPRD1 | Delta-type opioid receptor | Delta opioid receptor antagonist | ANTAGONIST | https://conductscience.org/library/genes/4985 |
| OPRK1 | Kappa-type opioid receptor | Kappa opioid receptor partial agonist | PARTIAL AGONIST | https://conductscience.org/library/genes/4986 |
| OPRM1 | Mu-type opioid receptor | Mu opioid receptor antagonist | ANTAGONIST | https://conductscience.org/library/genes/4988 |
Source ChEMBL
Diseases14
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Disease | Open Targets' stage | Stage reported by | Reports | Of them trials | Its drugs |
|---|---|---|---|---|---|
| alcohol dependence | Approval | ATC | 13 | 11 | https://conductscience.org/library/drugs?q=MONDO_0007079 |
| Pruritus | Phase 2 | ClinicalTrials.gov and TTD | 3 | 2 | https://conductscience.org/library/drugs?q=HP_0000989 |
| Chronic pain | Phase 1/2 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=HP_0012532 |
| Parkinson disease | Phase 2 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0005180 |
| gambling behaviour | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=EFO_0004699 |
| impulse control disorder | Phase 2 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0001162 |
| metabolic dysfunction-associated steatohepatitis | Phase 2 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0007027 |
| opioid use disorder | Phase 1 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=EFO_0010702 |
| primary biliary cholangitis | Phase 2 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0005388 |
| respiratory depression | Phase 3 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=EFO_0009842 |
1 to 10 of 14Source Open Targets
See all 14 diseasesTrials36
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT00812461 | Efficacy of Nalmefene in Patients With Alcohol Dependence | Phase 3 | 678 | 2013-07-09 | nalmefene | Its name | ClinicalTrials.gov |
| NCT00811941 | Safety and Efficacy of Nalmefene in Patients With Alcohol Dependence | Phase 3 | 665 | 2013-08-07 | nalmefene | Its name | ClinicalTrials.gov |
| NCT00811720 | Efficacy of Nalmefene in Patients With Alcohol Dependence | Phase 3 | 598 | 2013-07-09 | nalmefene | Its name | ClinicalTrials.gov |
| NCT02382276 | A Long-term Extension Study for the Phase 3 Study of Nalmefene (339-14-001) in Patients With Alcohol Dependence | Phase 3 | 405 | 2020-07-20 | nalmefene | Its name | ClinicalTrials.gov |
| NCT03096730 | Effect of Dexmedetomidine Combined With Low-dose Nalmefene on Preventing Remifentanil-induced Postoperative Hyperalgesia | 150 | 2021-08-03 | nalmefene | Its name | ClinicalTrials.gov | |
| NCT04828005 | Pharmacodynamic Evaluation of Intranasal Nalmefene | Phase 1 | 84 | 2025-07-14 | nalmefene | Its name | ClinicalTrials.gov |
| NCT04759768 | Pharmacokinetic Evaluation of Intranasal Nalmefene | Phase 1 | 68 | 2024-08-13 | nalmefene | Its name | ClinicalTrials.gov |
| NCT02442687 | JKB-121 for the Treatment of Nonalcoholic Steatohepatitis | Phase 2 | 65 | 2019-01-07 | JKB-121 | Its name | ClinicalTrials.gov |
| NCT05219669 | Pharmacokinetic Evaluation of Intranasal Nalmefene Using Three Dosing Regimens | Phase 1 | 24 | 2024-08-05 | nalmefene | Its name | ClinicalTrials.gov |
| NCT06719986 | Pharmacodynamic Evaluation of Intramuscular Nalmefene Autoinjector 1.5 mg Compared to Intranasal Narcan 4 mg | Phase 1 | 24 | 2025-07-03 | nalmefene | Its name | ClinicalTrials.gov |
1 to 10 of 36
See all 36 trialsComparisons in its trials11
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Nalmefene 18.06 mg vs Placebo: serious adverse events | 7 of 341 | 14 of 337 | 678 | NCT00812461 | Trial comparisons |
| Nalmefene 18.06 mg vs Placebo: serious adverse events | 35 of 501 | 8 of 164 | 665 | NCT00811941 | Trial comparisons |
| Nalmefene 18.06 mg vs Placebo: serious adverse events | 17 of 302 | 18 of 296 | 598 | NCT00811720 | Trial comparisons |
| Intranasal Nalmefene vs Intramuscular Nalmefene: deaths from any cause | 0 of 66 | 0 of 68 | 134 | NCT04759768 | Trial comparisons |
| Intranasal Nalmefene vs Intramuscular Nalmefene: serious adverse events | 0 of 66 | 0 of 68 | 134 | NCT04759768 | Trial comparisons |
| Intranasal Nalmefene vs Intranasal Naloxone: deaths from any cause | 0 of 61 | 0 of 60 | 121 | NCT04828005 | Trial comparisons |
| Intranasal Nalmefene vs Intranasal Naloxone: serious adverse events | 0 of 61 | 0 of 60 | 121 | NCT04828005 | Trial comparisons |
| Low Dose Naltrexone vs Nalmefene: deaths from any cause | 0 of 8 | 0 of 3 | 11 | NCT03278886 | Trial comparisons |
| Low Dose Naltrexone vs Nalmefene: serious adverse events | 1 of 8 | 0 of 3 | 11 | NCT03278886 | Trial comparisons |
| Low Dose Naltrexone vs Nalmefene: Number of Participants With Adherence Assessed Via Riboflavin in the Urine Confirming Adherence | 1 of 8 | 0 of 2 | 10 | NCT03278886 | Trial comparisons |
1 to 10 of 11
See all 11 comparisons in its trialsPapers from its trials14
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
| PMID | Listed as | Trials listing it | Source |
|---|---|---|---|
| 23562264 | RESULT | 1 | PubMed |
| 23237314 | RESULT | 1 | PubMed |
| 41807006 | DERIVED | 1 | PubMed |
| 41642634 | DERIVED | 1 | PubMed |
| 37530456 | DERIVED | 1 | PubMed |
| 37496452 | DERIVED | 2 | PubMed |
| 36859316 | DERIVED | 1 | PubMed |
| 36318027 | DERIVED | 1 | PubMed |
| 35426492 | DERIVED | 1 | PubMed |
| 33682527 | DERIVED | 1 | PubMed |
1 to 10 of 14
See all 14 papers from its trialsTests in its trials4
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
| Test | Trials naming it as an outcome | As a primary outcome | Source |
|---|---|---|---|
| Balloon Risk | 1 | 0 | ConductCognition |
| Delay Discounting | 1 | 0 | ConductCognition |
| Monetary Incentive Delay | 1 | 1 | ConductCognition |
| Stop-Signal Task | 1 | 1 | ConductCognition |
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL982
GET https://conductscience.org/api/drugs/v1/CHEMBL982/trials?page=2